Crocetin inhibits choroidal neovascularization in both in vitro and in vivo models
Experimental Eye Research · 2024
DOI: 10.1016/j.exer.2023.109751 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental Eye Research, 2024. Verfasst von Caixia Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei, China. Hauptthemen laut MEDLINE: Endothelial Cells, Choroidal Neovascularization. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Natural Science Foundation of Hebei Province.
Abstract (Originalsprache)
Choroidal neovascularization (CNV) is the primary pathogenic process underlying wet age-related macular degeneration, leading to severe vision loss. Despite current anti-vascular endothelial growth factor (VEGF) therapies, several limitations persist. Crocetin, a major bioactive constituent of saffron, exhibits multiple pharmacological activities, yet its role and mechanism in CNV remain unclear. Here, we investigated the potential effects of crocetin on CNV using in vitro and in vivo models. In human umbilical vein endothelial cells, crocetin demonstrated inhibition of VEGF-induced cell proliferation, migration, and tube formation in vitro, as assessed by CCK-8 and EdU assays, transwell and scratch assays, and tube formation analysis. Additionally, crocetin suppressed choroidal sprouting in ex vivo experiments. In the human retinal pigment epithelium (RPE) cell line ARPE-19, crocetin attenuated cobalt chloride-induced hypoxic cell injury, as evidenced by CCK-8 assay. As evaluated by quantitative PCR and Western blot assay, it also reduced hypoxia-induced expression of VEGF and hypoxia-inducible factor 1α (HIF-1α), while enhancing zonula occludens-1 expression. In a laser-induced CNV mouse model, intravitreal administration of crocetin significantly reduced CNV size and suppressed elevated expressions of VEGF, HIF-1α, TNFα, IL-1β, and IL-6. Moreover, crocetin treatment attenuated the elevation of phospho-S6 in laser-induced CNV and hypoxia-induced RPE cells, suggesting its potential anti-angiogenic effects through antagonizing the mechanistic target of rapamycin complex 1 (mTORC1) signaling. Our findings indicate that crocetin may hold promise as an effective drug for the prevention and treatment of CNV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei, China.
- Department of Ophthalmology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei, China. Electronic address: qinglishang@hb2h.com.
Förderung
- Natural Science Foundation of Hebei Province
Zitieren
APA
Wang, C., Li, X., Su, J., Duan, J., Yao, Y., & Shang, Q. (2024). Crocetin inhibits choroidal neovascularization in both in vitro and in vivo models. Experimental Eye Research. https://doi.org/10.1016/j.exer.2023.109751
Vancouver
Wang C, Li X, Su J, Duan J, Yao Y, Shang Q. Crocetin inhibits choroidal neovascularization in both in vitro and in vivo models. Experimental Eye Research. 2024. doi:10.1016/j.exer.2023.109751
BibTeX
@article{Wang2024,
author = {Wang, Caixia and Li, Xuejing and Su, Jing and Duan, Jialiang and Yao, Yimin and Shang, Qingli},
title = {Crocetin inhibits choroidal neovascularization in both in vitro and in vivo models},
journal = {Experimental Eye Research},
year = {2024},
doi = {10.1016/j.exer.2023.109751}
}
EUVIMED